Drugs / GST-HG131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04499443 | Aug 2020 → Mar 2021 | hepatitis B virus infection | Fujian Cosunter Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06263959 | Dec 2023 → Apr 2025 overdue | chronic hepatitis B virus infection | Fujian Akeylink Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07709520 Background | Jul → Oct 2026 expected | chronic hepatitis B virus infection | Fujian Akeylink Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GST-HG131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04499443 ↗ |
| Modality | Small molecule | “GST-HG131, a novel dihydroquinolizinone (DHQ) compound” PMID 35404074 ↗ Apr 2022 |